ArticleBiomedical optics express2019
Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced Raman spectroscopy.
Article in Biomedical optics express, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 68 citations in OpenAlex.
- LncRNA HMGA2-AS1 promotes postoperative recurrence in non-muscle-invasive bladder cancer by sponging miR-367-3p to activate YAP1.World journal of surgical oncology · 2026Article
- Review
- Identification and Evaluation of the Urinary Microbiota Associated With Bladder Cancer.Cancer innovation · 2025Article
- Review
- Urine-based SERS and multivariate statistical analysis for identification of non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.Analytical and bioanalytical chemistry · 2024Article
- Bladder cancer: non-coding RNAs and exosomal non-coding RNAs.Functional & integrative genomics · 2024Review
- Tannic Acid Impedes the Proliferation of Bladder Cancer Cells by Elevating Mitochondrial Pathways of Apoptosis.Cell biochemistry and biophysics · 2024Article
- Early cancer detection by SERS spectroscopy and machine learning.Light, science & applications · 2023Article
- Rapid and precise detection of cancers via label-free SERS and deep learning.Analytical and bioanalytical chemistry · 2023Article
- Identification of late-life depression and mild cognitive impairment via serum surface-enhanced Raman spectroscopy and multivariate statistical analysis.Biomedical optics express · 2023Article
- Molecular Fingerprint Detection Using Raman and Infrared Spectroscopy Technologies for Cancer Detection: A Progress Review.Biosensors · 2023Review
- The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer.Biomedicines · 2023Review
- Development and Validation of Nomograms Predicting the 5- and 8-Year Overall and Cancer-Specific Survival of Bladder Cancer Patients Based on SEER Program.Journal of clinical medicine · 2023Article
- Rapid Diagnosis of Ductal Carcinoma In Situ and Breast Cancer Based on Raman Spectroscopy of Serum Combined with Convolutional Neural Network.Bioengineering (Basel, Switzerland) · 2023Article
- Prediction of anticancer drug resistance using a 3D microfluidic bladder cancer model combined with convolutional neural network-based image analysis.Frontiers in bioengineering and biotechnology · 2023Article
- Rapid Detection of Recurrent Non-Muscle Invasive Bladder Cancer in Urine Using ATR-FTIR Technology.Molecules (Basel, Switzerland) · 2022Article
- Micro-Ultrasound in the Diagnosis and Staging of Prostate and Bladder Cancer: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2022Review
- Trends in Application of SERS Substrates beyond Ag and Au, and Their Role in Bioanalysis.Biosensors · 2022Review
- Article
- Label-Free Sensing with Metal Nanostructure-Based Surface-Enhanced Raman Spectroscopy for Cancer Diagnosis.ACS applied nano materials · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The assessment of the muscle invasion of bladder cancer typically plays a crucial role in therapeutic decision-making and has significant impacts on the recurrence rate and survival rate. Although histopathology is sufficiently accurate and usually served as the gold standard for bladder cancer diagnosis, it is invasive, time-consuming, and requires intensive sample preparation by a well-trained pathologist to achieve an optimal diagnosis. Therefore, a fast and noninvasive method to accurately identify non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is in demand. In this study, the SERS technique combined with the PLS-LDA method based on a small amount of blood serum samples is employed to distinguish healthy volunteers, NMIBC, and MIBC patients. According to the results, the overall diagnostic accuracy is 93.3%. The diagnostic accuracies are 97.8% and 93.2% for healthy versus bladder cancer groups and NMIBC versus MIBC groups, respectively. Therefore, the proposed method has demonstrated excellent performance on accurately identifying muscle invasion of bladder cancer, which can assist timely diagnosis and proper treatment for bladder cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.